The study examines how well these antibiotic treatments work in patients who can receive care outside the hospital. The medications are taken by mouth, and the treatment period lasts for 7 days. During this time, patients will be monitored to see if their fever goes away and if they experience any other health issues.

Patients will be followed for 30 days after starting treatment. The main focus is to determine if using amoxicillin-clavulanate alone works as effectively as using it together with ciprofloxacin. The study will track various aspects of patient health, including whether the fever returns, if hospital admission becomes necessary, and any side effects from the medications.

The purpose of the study is to assess whether stopping antibiotics after three days is as safe as continuing them for a longer period in patients with high-risk febrile neutropenia. Participants will receive one of the antibiotics mentioned above, or a placebo, through intravenous infusion, which means the medication is delivered directly into a vein. The study will last up to 42 days, during which the health of the participants will be closely monitored to ensure their safety and to observe any potential complications.

Throughout the study, researchers will look for any serious medical complications, such as the need for intensive care or the development of severe infections. They will also track the occurrence of other infections, the duration of hospital stays, and any changes in the use of antibiotics. The goal is to find a treatment strategy that is both effective and minimizes the use of antibiotics, which can help reduce the risk of antibiotic resistance and other side effects.